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Rheumatoid arthritis (RA) is an autoimmune disorder whose treatment is mostly restricted
to pain and symptom management and to the delay of joint destruction. Mesenchymal
stem/stromal cells from the umbilical cord tissue (UC-MSCs) have previously been
proven to be immunomodulatory and more efficient than bone marrow-derived MSCs
in causing remission of local and systemic arthritic manifestations in vivo. Given the
paracrine nature of UC-MSC activity, their application as active substances can be
replaced by their secretome, thus avoiding allogeneic rejection and safety issues related
to unwanted grafting. In this work, we aimed at demonstrating the viability of applying
the 3D-primed UC-MSC secretome for the amelioration of arthritic signs. A proteomic
analysis was performed to both, media conditioned by UC-MSC monolayer (CM2D) and
3D cultures (CM3D). The analysis of relevant trophic factors confirmed secretome profiles
with very significant differences in terms of therapeutic potential. Whereas, CM3D was
characterised by a prevailing expression of anti-inflammatory cytokines such as IL-10
and LIF, along with trophic factors involved in different mechanisms leading to tissue
regeneration, such as PDGF-BB, FGF-2, I-309, SCF, and GM-CSF; CM2D presented
relatively higher levels of IL-6, MCP-1, and IL-21, with recognised pro-inflammatory
roles in joint disease and pleiotropic effects in the progression of rheumatoid arthritis
(RA). Accordingly, different motogenic effects over mouse chondrocytes and distinct
capacities of inducing glycosaminoglycan synthesis in vitro were observed between
CM3D and CM2D. Finally, the evaluation of arthritic manifestations in vivo, using an
adjuvant-induced model for arthritis (AIA), suggested a significantly higher therapeutic
potential of CM3D over CM2D and even UC-MSCs. Histological analysis confirmed a
faster remission of local and systemic arthritic manifestations of CM3D-treated animals.
Overall, the results show that the use of UC-MSC CM3D is a viable and better strategy
than direct UC-MSC administration for counteracting AIA-related signs. This strategy
represents a novel MSC-based but nonetheless cell-free treatment for arthritic conditions
such as those characterising RA.
Keywords: mesenchymal stem/stromal cells, umbilical cord tissue, 3D culture, secretome, arthritic signs,
rheumatoid arthritis
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INTRODUCTION
The destruction and functional disability of joint tissues caused
by arthritis impart a massive burden to health services
worldwide. There are two basic types of arthritis: osteoarthritis
(OA), a degenerative condition that is the result of increased
wear and tear on joints, and autoimmune-based arthritis,
such as rheumatoid arthritis (RA), which produces systemic
inflammatory joint symptoms, with a greater incidence in
synovial tissues. OA may also produce inflammatory symptoms,
but primarily destroys joint cartilage over time. Neither form
of arthritis has yet a treatment, which is able to reverse joint
tissue wear out. The available alternatives are restricted to pain
and symptom management and/or to prevent or delay further
joint destruction. Efforts to discover new target therapies have
achieved some success. However, these new approaches are very
expensive and none of the currently widely used biological agents
reaches long-term drug-free remission (1, 2). RA is a systemic
disease and the mechanisms behind its symptoms are complex
and have not yet been fully uncovered. The innate immune
system, through activation of Toll-like receptors, contributes
to a joint pathophysiology characterised by the recruitment
of aberrant inflammatory cells, such as T-cell, B-cell, and
macrophages, that together with periarticular factors, such as
adipocytokines, cause chronic joint inflammation (3).
Given the lack of expression of MHC Class II, and residual
expression of MHC Class I, mesenchymal stromal/stem cells
(MSCs) are thought to have immune-privileged properties
and as such may be delivered in the absence of HLA
matching and/or immunosuppression (4–6). Additionally, MSCs
have immunomodulatory properties and as such have been
successfully applied for the treatment of inflammatory and
immune-mediated adverse reactions, such as graft vs. host disease
(GVHD), organ rejection after transplantation, allergy, and
autoimmune diseases (7–11).
Autoimmune-driven joint destruction, caused by persistent
inflammation, renders RA a possible clinical target for cartilage
and bone repair using MSCs (12). Indeed, previous results, using
amouse adjuvant-inducedmodel for arthritis (AIA), showed that
autologous bone marrow-derived MSCs (BM-MSCs), injected
in the joints were able to reduce joint swelling and cartilage
destruction, by decreasing the levels of TNF-α. These cells
were shown to integrate into the synovium (13). More recently,
conditioned medium from the same BM-MSCs was used for
treatment (with increased levels of IL-10) significantly reducing
histopathological signs of AIA, cartilage damage and suppressing
immune responses by reducing aggrecan cleavage, enhancing
Treg function and adjusting the Treg:Th17 ratio (14).
Alternatively to BM-MSCs, MSCs from the umbilical cord
stromal tissue, or Wharton’s jelly (UC-MSCs), can be safely used
for allogeneic approaches given their lack of immunogenicity
and their marked capacity for localised immunosuppression (15).
This immunomodulatory effect is not contact-dependent and
is thought to be mostly due to secreted paracrine factors. In
addition, UC-MSCs have advantages over otherMSCs given their
relatively easy and non-invasive procurement, higher expansion
potential and overall higher potency to differentiate into more
diverse specialised cells originating from the three germ layers
(16, 17).
In our previous studies we have shown that the
immunomodulatory properties of a particular population
of human UC-MSCs, when compared to human BM-MSCs,
were less immunogenic, suitable for xenotransplantation
without inducing immunologic infiltrates, and had higher
immunosuppression activity than BM-MSCs. Furthermore,
unlike BM-MSCs, UC-MSCs did not need prior activation
or priming to exert their immunomodulatory effects in
vivo. Several gene and protein expression profile differences
were found between UC-MSCs and BM-MSCs that could
explain such observations, namely the increased expression of
immunomodulatory surface proteins such as CD200, CD273,
CD274, and cytokines such as IL-1β , IL-8, LIF, and TGF-β2
by UC-MSCs (6). In another comparative study, this time
in the context of cutaneous wound healing, UC-MSCs have
shown to secrete considerably higher amounts of G-CSF, EGF,
FGF-2, and KGF than BM-MSCs, with concomitant improved
motogenic effects over keratinocytes and fibroblasts, as well as
enhanced pro-angiogenic activity (18). Accordingly, UC-MSCs
were shown to potentially induce the regenerative capacity
of tissues in vivo by attracting other endogenous MSCs via a
unidirectional, UC-MSC-specific, G-CSF-mediated mechanism
(18). More relevant to this study, such population of UC-MSCs
when transplanted in vivo, in a rat AIA model, showed to be
non-immunogenic, to have immunosuppressive properties
through the inhibition of T-cell proliferation and induction of
Tregs, and to promote an impressive remission of local and
systemic arthritis manifestations (19, 20). Interestingly, by taking
advantage of the 3D greater cell-to-cell communication and
cell-to-extracellular matrix (ECM) interactions, the same cells
cultured as self-aggregated spheroids could be primed toward
a better therapeutic phenotype, as demonstrated in a wound
healing context (21).
In this work, we aimed at demonstrating the feasibility
of applying a 3D-culture-based UC-MSC priming strategy
to improve the efficacy of the resulting secretome for the
treatment of inflammatory arthritis. Differences in proteomic
profiles and in vitro and in vivo therapeutic potentials were
confirmed between secretomes produced in either 3D spinner
flask bioreactors or UC-MSCs cultured under conventional
two-dimensional (2D) monolayer conditions. The results
clearly showed an improved efficacy of a UC-MSC 3D-
derived secretome for the amelioration of experimental
AIA manifestations, even when compared with the direct
administration of UC-MSCs. The potential mechanisms behind
our observations are discussed, as we disclose the potential use
of a UC-MSC 3D-primed secretome, or some of its components,
as active substances for Advanced Therapy Medicinal Products
(ATMP) for the treatment of RA.
MATERIALS AND METHODS
Reagents
Antibodies and their respective isotypes were acquired from
BioLegend (San Diego, CA, USA) unless stated otherwise.
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Cell culture media and supplements were purchased from
Sigma-Aldrich (Madrid, Spain), unless otherwise stated. FBS,
Formalin, Trypsin/EDTA (ethylenediamine tetra-acetic acid),
Eosin Y and Harris’s haematoxylin: Gibco (Life Technologies,
Madrid, Spain). BCA protein assay kit: Novagen (San Diego, CA,
USA). BlyscanTM Sulfated Glycosaminoglycan Assay kit: Biocolor
(Carrickfergus, UK). Entellan R©: Merck (Darmstadt, Germany).
Flow-CytomixTM: eBioscience. TGF-β1: Tebu-bio (Le-Parray-en-
Yvelines, France). Tissue Tek R© O.C.T.TM: Sakura (Zoeterwoede,
The Netherlands). Xylene: EMD Chemicals, Inc. (Gibbstown, NJ,
USA).
UC-MSC Isolation and Culture
UC-MSC Isolation
This study was approved by the Ethics Committee of the
Hospital Dr. José de Almeida (Cascais, Portugal), in the
scope of a research protocol between ECBio (Research &
Development in Biotechnology, S.A.) and HPP Saúde (Parcerias
Cascais, S.A.). Umbilical cord donations, with written informed
consents, as well as umbilical cord procurement, were made
according to Directive 2004/23/EC of the European Parliament
and of the Council of 31 March 2004 on setting standards
of quality and safety for the donation, procurements, testing,
processing, preservation, storage, and distribution of human
tissues and cells. UC-MSCs were isolated from umbilical
cords of healthy new-born babies, upon informed consent
of healthy parturients, as previously described (22). Cells
were cryopreserved in minimum essential medium Eagle alpha
modification (α-MEM) containing 10% dimethyl sulfoxide
(DMSO) stock solution and 20% foetal bovine serum (FBS),
using a controlled rate of temperature decrease. When needed,
UC-MSCs cryopreserved between passage 3 (P3) and P5
were thawed and further expanded during a maximum of
30 cumulative population doublings (cPDs), corresponding to
P12 in culture. UC-MSCs are known to undergo at least
55 cPDs (P22) before reaching senescence, keeping MSC
phenotype (21).
Three-Dimensional (3D) Culture
For 3D cultures, spinner vessels (125mL) with ball impeller
containing α-MEM supplemented with 15% FBS were inoculated
with single cell suspensions at a concentration of 1 × 106
cells/mL. To promote cell aggregation spinner vessels were
stirred at 80 rpm and kept at 37◦C in a humidified atmosphere
of 5% CO2 for 24 h. After this period, half of the cell culture
supernatant was replaced by fresh medium supplemented with
10% FBS (v/v). Culture medium was replaced every 3–4 days and
the stirring rate was adjusted to 110 rpm to maintain spheroid
size below 350µm.
Two-Dimensional (2D) Monolayer Culture
For two-dimensional (2D), static monolayer, cultures, cells were
seeded at a density of 1× 104 cells/cm2 in α-MEM supplemented
with 10% FBS and incubated at 37◦C in a humidified atmosphere
with 5% CO2. Cell passage was performed by Trypsin/EDTA
0.05% incubation for 5min every 72 h.
UC-MSC Characterisation
Flow Cytometry
Cell surface marker expression was analysed by flow cytometry in
both 2D and 3D cultures. Cell detachment from culture t-flasks
and dissociation from spheroids was performed by using 0.25%
Trypsin/EDTA. The resulting single cell suspension was washed
with 2% bovine serum albumin (BSA) in phosphate-buffered
saline (PBS). Detection of cell surface markers was performed
with the following antibodies and their respective isotypes after
incubation for 1 h at 4◦C: phycoerythrin (PE) anti-human CD105
(eBioScience, San Diego, CA, USA); APC anti-human CD73; PE
antihuman CD90; APC anti-human CD44; PerCP/Cy5.5 anti-
human CD45; fluorescein isothiocyanate (FITC) anti-human
CD34; FITC anti-human CD31; PerCP/Cy5.5 anti-human CD14;
Pacific Blue anti-human CD19 and pacific-blue anti-human
HLA-DR. All samples were acquired on a Gallios (Beckman
Coulter, Pasadena, CA, USA) and the results analysed with
Kaluza software (Beckman Coulter). A minimum of 1 × 104
events were acquired per surface marker. One replicate was
analysed per independent experiment (n= 4).
Tri-lineage Differentiation
Spheroids were dissociated into a single cell suspension
with 0.25% Trypsin/EDTA and transferred to appropriate
culture t-flasks for cell proliferation and expansion. To
induce adipogenic differentiation, UC-MSCs were incubated
in α-MEM supplemented with 20% FBS, 10µg/mL insulin,
200µM indomethacin, 0.5mM isobutylmetylxantine, and
1µM dexamethasone for 3 days and 1 day in medium
supplemented with 20% FBS and 10µg/mL insulin. To induce
osteogenic differentiation, cells were incubated in α-MEM
supplemented with 10% FBS, 10mM β-glycerol phosphate,
100 nM dexamethasone, and 50µg/mL ascorbate-2-phosphate.
Finally, to induce chondrogenic differentiation, cells were
maintained in suspension as pellets, incubated with Dulbecco’s
modified Eagle’s medium (DMEM) with 4mM glutamine and
1 g/L D-(+)-glucose, supplemented with 1% FBS, 6.25µg/mL
insulin, 10 ng/mL transforming growth factor (TGF)-β1, and
50µM ascorbate-2-phosphate. For cytochemical staining,
cells were fixed with paraformaldehyde 4% for 20min. In
adipogenic and osteogenic differentiation protocols, cells were
stained with Oil Red O for 10min and alkaline phosphatase
for 30min, respectively. For chondrogenic differentiation, the
chondrospheres were fixed in formalin, embedded in paraffin
and cut into sections of 5µm and stained with alcian blue for
30min. The presence of stained cells was confirmed by inverted
microscopy with phase contrast (Leica, DMIL HC, Wetzlar,
Germany).
Protein Quantification
For both 3D and 2D cultures, biomass was evaluated by total
protein quantification using a BCA protein assay kit, after cell
pellet lysis with 0.1M NaOH at 37◦C for 24 h.
UC-MSC Spheroid Visualisation and Measurement
Spheroids were observed by bright field microscopy (Olympus
CK30, Olympus, Tokyo, Japan) and their average diameter
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determined by a geometric mean of three diameters per spheroid
as previously described, using the following equation: average
diameter= (d1× d2× d3)1/3 (17, 23). Diameters were measured
using Motic Images Version 2.0 software (Xiamen, China).
Haematoxylin and Eosin Staining
Spheroids were suspended in Tissue Tek R© O.C.T.TM for
preparing 10µm cryosections. Slides were first stained with
Harris’s haematoxylin for 10min, followed by incubation with
HCl 1% (v/v) in 70% EtOH, and by Eosin Y staining for
2min. Slides were then submitted to increasing concentrations of
ethanol and finally incubated in xylene. Samples were mounted
with Entellan R©. Images were acquired on an Olympus CK30
inverted microscope and processed using Motic Images Version
2.0 software.
Conditioned Media (CM) Preparation
Conditioned media (CM) were produced from cells having
undergone the same number of cPDs. UC-MSC CM from 3D
spinner flask cultures (CM3D) was obtained by cell inoculation
as described above, subjected to successive medium adaptations:
FBS concentration was reduced to 5% at culture day 2. After
3 days, medium was changed with α-MEM without FBS and
volume adjusted to obtain a conditioning volume per cell
equivalent to that in the 2D system. After 48 h of conditioning,
CM3D was collected under sterile conditions. To produce UC-
MSC CM in 2D monolayer cultures (CM2D), 1.75 × 106 cells
were seeded in 175 cm2 culture t-flasks and kept in medium
supplemented with 5% FBS until they reached 90% confluence.
At this point, cells were washed with fresh α-MEM and medium
was replaced by α-MEMwithout FBS, to a final volume of 25mL.
After conditioning for 48 h, CM2D was harvested under sterile
conditions. The control sample consisted of α-MEM which was
never in contact with cells. CM3D, CM2D, and control were
10× concentrated using 3-kDa cut-off spin concentrators. Total
protein content of CM2D, CM3D and control was quantified
using a BCA protein assay kit. Samples were stored at −80◦C
until further use.
CM2D and CM3D Trophic Factor Quantification
Trophic factor concentrations within CM3D and CM2D samples
were measured using the Human 64-Plex Cytokine/Chemokine
Panel (Eve Technologies, Calgary, AB, Canada) or using
Flow-CytomixTM according to manufacturer’s recommendations.
All cytokines/chemokines, except for IL-6 and MCP-1, were
quantified by resorting to the multiplexing technology. IL-6
and MCP-1 detections were acquired on a Gallios (Beckman
Coulter) and the results were obtained using FlowCytomixTM
Pro 3.0 Software. Data is expressed in terms of productivity:
ng/mL/million cells/hour, normalised against the background
(α-MEM that was never in contact with cells) threshold
concentrations.
CM Testing in vitro
Mouse Chondrocyte (ATDC5) Cell Culture
Mouse chondrocytes (ATDC5) were seeded at 1 × 104 cells/cm2
and cultured in DMEM-F12 supplemented with 5% FBS, at
37◦C, in 5% CO2 humidified atmosphere until reaching 70–80%
confluence. Cell passage was performed by Trypsin/EDTA 0.25%
incubation for 5min every 72 h.
Scratch Assay
ATDC5 cells were seeded into 24-well plates at a density of
1.5 × 104 cells/cm2 with DMEM-F12 supplemented with 5%
FBS. Once at 90% confluence, scratches of ∼0.5mm in width
were performed on the monolayer with a sterile 200 µL pipette
tip. Immediately after, the cell surfaces were washed with PBS
and maintained in a final volume of 400 µL of DMEM-F12
supplemented either with CM2D, CM3D, all 10 × concentrated.
DMEM-F12, DMEM-F12:α-MEM (1:1) and DMEM-F12 with
5% FBS were also tested as negative, solvent and positive controls,
respectively. The area of the scratch, from the same field, was
measured at 0, 3, 6, 8, 10, 20, and 24 h post-scratch to evaluate cell
migration. Digital photographs were taken at an amplification
of 40× on Olympus CK30 microscope. Cellular migration was
analysed in the Motic Images Version 2.0 software by calculating
scratch closure, given as the total area occupied by the cells after
incubation with CM in relation to the initial scratch area at 0 h.
Three independent experiments in triplicates were considered.
Glycosaminoglycan Quantification
Glycosaminoglycans (GAG) were quantified in ATDC5 cell
culture supernatants. At a confluence of 60%, cells were
incubated with DMEM-F12 supplemented either with CM2D
or CM3D 10× concentrated. DMEM-F12, DMEM-F12:α-MEM
(1:1) and DMEM-F12 with 5% FBS were also tested as
negative, solvent and positive controls, respectively. After 24 h of
incubation, GAGs were determined using the BlyscanTM Sulfated
Glycosaminoglycan Assay kit, according to the manufacturer’s
instructions. A total of three independent experiments were
performed.
CM Testing in vivo
Adjuvant-Induced Arthritis (AIA) Model
All animal experiments were carried out with the permission of
the local animal ethical committee in accordance with the EU
Directive (2010/63/EU), Portuguese law (DL 113/2013) and all
relevant legislations. The experimental protocol was approved by
Direcção Geral de Alimentação e Veterinária (DGAV). Animals
were acclimatised before the experiments and housed in plastic
cages under standard laboratory conditions, fed commercial
chow, and acidified drinking water ad libitum.
Induction of the inflammatory reaction was achieved by
injecting Wistar rats (365–480 g; Charles River Laboratories,
France) with a single intradermal (i.d.) administration of 0.1mL
of a suspension of killed and dried Mycobacterium butyricum
in incomplete Freund’s Adjuvant—IFA (at 10 mg/mL) (Difco
Laboratories), into the sub-plantar area of the right hind paw
(24). Animals were randomly divided into groups (n = 3-
6). Treatment was initiated at day 7 after induction. Induced
animals were treated with different formulations: (i) one group
received PBS by intraperitoneal (i.p.) injection (Sham UC-
MSC group); (ii) another group received PBS by intra-articular
(i.a.) route of administration (Sham CM group); (iii) a third
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group received 2D-cultured UC-MSCs (1.7 × 106 cells per
injection in 4 consecutive days) by i.p. injection (UC-MSC
group); (iv) a fourth group received, by i.a. injection, 10×
concentrated CM2D (CM2D group); (v) one group received,
by i.a. injection, 10× concentrated CM3D (CM3D group); and
lastly, (vi) three animals received neither inflammation induction
nor any treatment and were used as a naïve control for histology
analysis (Control). No experimental group received 3D-cultured
UC-MSCs since full cell disaggregation from 3D aggregates has
proven very difficult with consequent risk of acute inflammation
and thrombosis. Animals treated intraperitoneally and the
respective control group (Sham UC-MSC group) received a
volume of 100 µL of the tested formulations per injection
(i.e., a total of 400 µL). Animals treated intrarticularly and the
respective control group (Sham CM group) received a volume
of 200 µL of the tested formulations per injection (i.e., a
total of 600 µL). I.p. injections were given for 4 consecutive
days. I.a. administrations, in a total of three, were performed
every-other-day. The experiment lasted for 57 days. To follow
the course of the disease, body weight and volume of right
and left paws measured by a water displacement method,
using a plethysmometer (Ugo Basile, Italy), were measured.
Blinding investigators to treatment groups were defined. Arthritis
was evaluated in ankle joints in a blinded manner using a
semiquantitative arthritic score based on the sum of the following
grades: 0 = normal; 1 = for each inflamed paw; 1 = tail
lesion; 1 = joint rigidity or deformity; 1 = wounded paw; 1
= infected paw; 1 = necrotic paw. The sum of the parameters
is calculated as an arthritic index (AI) with a maximum
possible score of 9. Photographs recorded the evolution
of clinical signs in all experimental groups. Animals were
sacrificed at day 57, necropsies and gross pathology examination
was conducted. The experiment was performed twice with
consistent observations, using two UC-MSC isolates (different
donors).
Collection of Paw Samples and Histopathological
Analysis
After the sacrifice, animal paws were collected, fixed in
10% buffered formalin and decalcified with 10% formic
acid to undergo histopathological analysis. In order to
evaluate the surroundings of the site of application, fixed
decalcified paws were processed for embedding in paraffin
wax by using routine protocol. Sections (5µm thick) were
stained with haematoxylin and eosin (H&E). The slides
were examined using light microscopy using an Olympus
BX 40 microscope coupled with an Olympus DP 10 camera
(Olympus, Shinjuku, Tokyo, Japan). Digital photographs were
taken at an amplification of 100×, except for the control that
was acquired at an amplification of 40×. The histological
samples were evaluated for synovial inflammation and bone
erosion. Synovial inflammation was scored as follows: 0- no
inflammation; 1- slight synovitis with some cell infiltration; 2-
moderate synovitis with moderate cell infiltration; 3- extensive
synovitis with a moderate number of infiltrating cells; 4-
extensive and severe synovitis, with the presence of numerous
inflammatory cells. Bone erosion was scored as follows: 0-
no erosion; 1- small areas of resorption; 2- numerous areas
of resorption; 3- extensive osteolysis; 4- extensive and severe
osteolysis.
Statistical Analysis
Statistical analyses were performed in GraphPad Prism v6.0
software (La Jolla, CA, USA). To estimate the significance of
the differences of trophic factor quantification and of the data
obtained from GAG production in vitro, multiple t-tests and
Student’s paired t-test with one-tailed distribution were used,
respectively. The two-way ANOVA with Tukey’s post-hoc test
was performed for the in vitro scratch assay data. Results are
presented as means ± standard error of the mean (SEM),
except where indicated and p-values are presented for statistically
significant results (∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001).
RESULTS
Pre-conditioning UC-MSCs in
Tri-dimensional (3D) Culture Conditions
Results in a Secretome Richer in
Therapeutically Relevant Trophic Factors
Three-dimensional (3D) spheroids from UC-MSCs were
obtained using a spinner flask suspension culture. Measurements
of spheroids were performed by phase-contrast images
throughout the whole culture period yielding the size-
distribution plot shown in Figure 1. Firstly, UC-MSCs form
small low-density cell aggregates of ∼100µm diameter (Day
2, Figures 1A,B). After 4 days, spheroid diameters were, on
average, 149.11 ± 0.57µm and 195.48 ± 5.48µm from day
5 to 7 of culture (Figures 1A,B). The results showed that
the formation of more dense and viable 3D structures from
day 4 onwards, with expected low diffusion rate of nutrients
(Figures 1B,C). Nevertheless, a necrotic centre in spheroids was
circumvented by maintaining the average spheroid size under
350µm (Figure 1C).
In the present work, we firstly verified if the 3D culture
conditions prompted the production of a secretome with higher
potential to counter AIA signs than that obtained by UC-MSCs
grown under 2D monolayer conditions. A comparative analysis
of a representative pool of trophic factors involved in relevant
immune-modulation and other relevant joint tissue regeneration
events was performed between CM3D and CM2D. The relative
productivity of such trophic factors was determined taking into
consideration cell populations kept in similar conditions in
terms of number of cells (with equivalent number of cPDs),
same medium volume and conditioning time. The only variable
in the experimental design was therefore the culture setup
for modulating cell phenotype: 2D vs. 3D. Figure 2 shows
the logarithm (Log10) of CM3D/CM2D ratio, representing
the relative trophic factor productivity in 3D vs. 2D culture
conditions normalised against the background medium that was
never in contact with cells (α-MEM).
The results depicted in Figure 2 clearly show some interesting
differences in specific trophic factor productivities that could
result different therapeutic activities between CM3D and CM2D.
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FIGURE 1 | UC-MSCs form viable three-dimensional spheroids. (A) Representative phase contrast images of UC-MSC spheroids from days 2, 5 and 7 of culture.
(B) UC-MSC spheroid size during culture time. (C) Representative image of UC-MSC spheroid sections from day 7 of culture stained with H&E. Scale bar = 100µm.
n = 7.
FIGURE 2 | UC-MSCs display differences in specific trophic factor productivities that could entail different therapeutic activities between CM3D and CM2D.
Quantification in CM3D and CM2D of a representative pool of trophic factors involved in relevant immune-modulation and other RA-relevant regenerative cascades of
events. Data is expressed as the logarithm of the ratio between CM3D and CM2D productivities (ng/mL of the growth factors or cytokines/million cells/hour) corrected
by subtracting the background (α-MEM). Plotted ratios are mean ± SD. n = 3. *p < 0.05, **p < 0.01, and ***p < 0.001.
CM3D was characterised by a prevailing expression of anti-
inflammatory cytokines such as IL-10 and LIF, as well as
trophic factors involved in different mechanisms leading to tissue
regeneration, mainly PDGF-BB, FGF-2, I-309, SCF, and GM-
CSF (25–29). In turn, CM2D was characterised by relatively
higher levels of cytokines with recognised pleiotropic roles in
the progression of inflammatory arthritis, such as IL-6, MCP-
1, and IL-21 (30–32). To confirm if the differences observed
in trophic factor profiles would indeed translate into different
paracrine activities in vitro, we set forward to evaluate (i)
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the relative capacity of CM3D and CM2D to induce motility
of joint chondrocytes and (ii) the relative capacity of CM3D
and CM2D to induce glycosaminoglycan (GAG) synthesis, two
important mechanisms connected to joint regeneration and
arthritic aetiology.
CM3D Has a Higher Motogenic Activity
Over Mouse Chondrocytes in vitro
The relative capacity of CM3D and CM2D to promote
chondrocyte migration was evaluated by scratch assays. Scratch
areas were monitored for 24 h post-scratch. The results depicted
in Figure 3 confirm significant differences between the paracrine
activities of CM3D and CM2D. The CM3D supplement
promoted a ∼1.5-fold increase in chondrocyte migration
capacity 24 h post-scratch when compared to CM2D, a fact that
could be explained by e.g., relatively higher CM3D expression
of PDGF-BB, IL-10, and FGF-2, all with recognised mitogenic,
protective, and motogenic activities over chondrocytes (33–35).
CM2D Has a Higher Capacity of Inducing
Glycosaminoglycan (GAG) Synthesis in
vitro
Differences between the paracrine activities of CM3D and CM2D
were further confirmed in vitro by evaluating their relative
capacities to induce GAG synthesis. GAG concentration was
quantified in the supernatant after 24 h of incubation. The results
depicted in Figure 4 clearly show a ∼2-fold increase in GAG
induction by CM2D when compared to CM3D, a fact that could
be explained e.g., by the relatively higher CM2D expression of IL-
6 which has been shown to stimulate fibroblastic GAG synthesis
and chondrocyte cartilage matrix production in vitro (36, 37).




Given the in vitro evidence that CM3D and CM2D had in fact
different paracrine activities regarding important mechanisms
connected to joint regeneration and arthritic aetiology, we set
out to evaluate the potential benefits of UC-MSCs primed by 3D
culturing for reverting AIA signs in vivo.
The AIA model is useful for addressing the protective effects
against manifestations typifying the late stage of entrenched
chronic arthritis, sharing several pathological features with RA.
The model is established by injecting Mycobacterium butyricum
in incomplete Freund’s Adjuvant into the sub-plantar area of
Wistar rats’ right hind paws. In our well-characterised setup,
the disease shifts from a local arthritis stage to a systemic
polyarthritis condition by day 13 after induction (20, 38).
Indeed, we previously refined and characterised AIA by studying
the time course of the disease, introducing new evaluation
methods and identifying the main stages of the disease (24).
FIGURE 4 | CM2D has a higher capacity of inducing glycosaminoglycan
(GAG) synthesis in vitro. GAG production by mouse chondrocytes (ATDC5)
was quantified in cell culture supernatant from cultures maintained in
DMEM-F12 (negative control) or DMEM-F12 supplemented either with CM2D,
CM3D, or 5% FBS (positive control). n = 3. *p < 0.05.
FIGURE 3 | CM3D has a higher motogenic activity over mouse chondrocytes in vitro. Graphical representation of the percentage of reduction in the scratched area of
mouse chondrocytes (ATDC5) evaluated through in vitro scratch assay after 10 h, 20 h and 24 h. ATDC5 cells were maintained in DMEM-F12 (negative control) or
DMEM-F12 supplemented either with CM2D, CM3D or 5% FBS (positive control). n = 3. **p < 0.01, and ***p < 0.001.
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One day after the disease induction, the induced paw volume
more than doubled and haematological parameters completely
changed, corresponding to the first disease phase. Two weeks
after induction, another stage occurred when the disease shifted
from the local arthritis form toward a systemic polyarthritis along
with an additional increase of the paw volume (20, 38). Animal
body weight also reached the minimum values and radiographic
observable joint lesions increased accordingly (24). Starting the
treatment at day 13 or later hampers the possibility to stop
and reverse joint erosion (data not shown). Early recovery on
body weight was obtained for animals treated at day 7 when
compared with animals treated later (data not shown). As such,
our treatment protocol started at day 7 post-induction and lasted
for 57 days. No adverse effects were observed during or after the
treatment period.
I.a. administration of CM3D and CM2D was performed
and compared to the better performing route for UC-MSC
administration, which had been found previously to be i.p. in
the same AIA model (20). No experimental group received
3D-cultured UC-MSCs since full cell desegregation from 3D
aggregates has proven very difficult with consequent risk of acute
inflammation and thrombosis. The body weight, inflammatory
swelling, clinical scoring through arthritic index (AI), and
histopathological endpoints were measured.
The time course of body weight is illustrated in Figure 5A.
Given the transient nature of the AIA model, animals in
all groups ultimately recovered from AIA manifestations and
regained their natural body weights. However, weight loss was
less prominent in animals treated with CM3D, especially between
days 20 and 30 where the arthritic signs reached their highest
intensity.
The hind paw volume was monitored by water displacement
as a function of time after disease induction (Figure 5B). Swelling
of adjuvant-injected right paws with erythema became evident
within 1 day after induction. As seen in Figure 5B, animals from
all treatment groups (UC-MSC, CM3D, and CM2D) showed
FIGURE 5 | CM3D ameliorates adjuvant-induced arthritis (AIA) manifestations in vivo. The course of the disease was followed by measuring the (A) body weight, (B)
the volume of the right paw (induced paw) and by (C) quantifying the disease score (arthritic index) of UC-MSC-, CM3D-, and CM2D-treated animals, and
corresponding controls (Sham). Upward arrows represent the days of i.a. injections (CM administration). Downward arrows represent the days of i.p. injections
(UC-MSC administration). n = 4 for sham groups; n = 6 for all other groups.
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ameliorated swelling. Nevertheless, the effect elicited by CM3D,
as reflected by a considerable swelling reduction rate from day 15
onwards, conveys an unprecedented capacity for concomitantly
prevent against the implantation and revert AIA inflammatory
signs in vivo.
The development course of AIA signs was also evaluated by
monitoring the evolution of the arthritic index (AI) as a function
of time after disease induction (Figure 5C). All UC-MSC-based
treatments resulted in amelioration of AIA manifestations when
compared to the Sham controls as seen at day 20. Notably,
treatment with CM3D resulted in more than a 2-fold reduction
in AIA severity at day 20, culminating in a 5-fold difference
at day 57, relatively to untreated animals. When compared to
CM2D, CM3D was able to prevent the development of the
AI more efficiently by a factor of ∼1.8-fold at day 20, and
still culminating with a 1.5-fold amelioration at day 57. The
amelioration effect of CM3D was not so pronounced when
compared to the administration of UC-MSCs at day 20 (1.5-fold),
although in the end the amelioration effect brought by CM3D
was still significant throughout the full experimental time frame
(Figure 5C).
The results of a more in-depth analysis of AIA manifestations
at day 57 are depicted in Figure 6. Representative hind-paw
photos of each experimental group clearly show that untreated
animals, belonging to control (Sham) groups, still presented
moderate-to-severe swelling encompassing the ankle, foot, and
digits, with multiple foci of necrosis, inflammation, secondary
infection, and joint deformity (Figures 6A,B). Notably, CM3D-
treated animals exhibited only minimal paw swelling, with
no signs of lesion (Figure 6E) when compared to CM2D-
(Figure 6D) and UC-MSC-treated (Figure 6C) animals that
still presented a moderate degree of swelling and moderate-
to-negligible signs of lesion. Accordingly, the histopathological
analysis of control (Sham) animals showed extensive osteoclastic
activity along with the presence of granulomas, affecting the
limits of the cartilage and bone tissues (Figures 6F,G,K,L). Bone
necrosis appeared mainly in the periphery where numerous
osteoclasts were noticed (Figures 6K,L). Synovitis was detected
in all cases which represented the initial phase of RA
(Figures 6F,G). No significant differences were observed between
the two Sham groups (i.a. vs. i.p.). In turn, UC-MSC-treated
animals still showed some signs of inflammation as seen by the
presence of granulomas in the osteolytic area (Figure 6M) and
of hyperplasic synovium membrane (Figure 6H). Finally, both
animals treated with CM2D and CM3D presented small foci
of synovitis with almost well-defined bone and cartilage tissue
stratification (Figures 6I,J). Moreover, the osteolysis degree
observed in CM3D-treated animals (Figure 6O) is lower than
that of animals treated with CM2D (Figure 6N), in which
granulomatous lesions are still present.
DISCUSSION
MSCs are known to modulate tissue regeneration through
trophic effects exerted by secreted cytokines and growth factors.
In fact, and contradicting the dogma that cells need to be
physically present to induce regeneration through mechanisms
involving homing, engrafting, and secretion of trophic factors
in response to local stimuli, our previous results have unlocked
the possibility of using the MSC secretome as active substance
for therapeutic formulations. By recreating a more physiological
environment within our 3D culture system, characterised by
tissue-like cell-to-cell and cell-to-ECM interactions, as well as the
presence of stress signals discharged by MSCs within the core
of self-aggregated spheroids (e.g., hypoxic and famine), we were
able to mimic many stimuli found within the lesion niche.
In this work, we aimed at demonstrating the viability of
applying this 3D-priming strategy to improve the efficacy of the
resulting UC-MSC secretome for counteracting the signs caused
by inflammatory arthritis. A comparative analysis of CM3D and
CM2D proteomes, comprehending a significant set of relevant
trophic factors, corroborated our previous finding that our 3D
conditions promoted different trophic profiles. Within our pool
of trophic factors, CM3D was marked by synthesis of mainly IL-
10, LIF, FGF-2, I-309, GM-CSF, eotaxin, and MIP-1α, and to a
lower extent G-CSF, PDGF-BB, 6CKine, and SCF. In turn, CM2D
was characterised by significantly higher expression of mainly
IL-6, MCP-1, and IL-21.
The impact of such differences was validated in vitro where
CM3D showed significantly higher motogenic activity over
chondrocytes when compared to CM2D. This could be explained
by e.g., relatively higher CM3D expression of e.g., IL-10, FGF-
2, and PDGF-BB (33–35). IL-10 was found to directly protect
chondrocytes in vitro through the inhibition of NOS2 and
MMP-3 expression. In turn, FGF-2 and PDGF-BB are potent
mitogens for articular chondrocytes which have also been found
to promote chondrogenic differentiation (33, 35, 39).
Different paracrine activities between CM3D and CM2D were
further validated in vitro by evaluating their relative capacities
to induce GAG synthesis. This time CM2D proved to be a
more potent inducer of GAG synthesis than CM3D, which could
be justified by the relatively higher CM2D expression of IL-
6. IL-6 was found to induce IL-1β-related collagen and GAG
biosynthesis and to stimulate cartilage matrix production in vitro
(37, 40).
Although in vitro indications suggested differential capacities
of CM3D and CM2D to induce important events connected
to tissue regeneration, their impact in the specific context
of AIA could not be directly extrapolated. For example,
although apparent benefits should be drawn from FGF-2-induced
chondrocyte motility in a OA context, FGF-2 expression in
RA patients has been closely associated with disease severity
(41). Recently, FGF-2 was even shown to cooperate with IL-
17 in the pathogenesis of autoimmune arthritis (42). Similarly,
while GAG production promoted by IL-6 is necessary for the
regeneration of functional cartilage in osteoarthritic patients,
self-antigenic GAGs were found to provoke autoimmune
dysfunctions that involve the expansion of GAG-binding
infiltrates, thus aggravating inflammatory conditions in RA
(43). The amelioration effects of either CM3D or CM2D on
arthritic signs would therefore be dependent on how the
overall synergistic activity within each of their trophic factor
compositions would interrelate with the AIA environment.
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FIGURE 6 | CM3D attenuates tissue destruction in adjuvant-induced arthritis (AIA) rats. (Panel I) Representative images of induced hind paws obtained from rats
treated with UC-MSCs, CM3D, and CM2D, and the respective controls (Sham), on day 57 after arthritis induction. Representative images of non-induced hind paw
(Continued)
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FIGURE 6 | (control) are also shown. (A–E) Macroscopic images of induced hind paws. (F–O) Representative photomicrographs from rat paw histological sections
stained with H&E revealing signs of (F–J) synovitis and/or (K–O) osteolysis. Specifically: (F) sham UC-MSC histological sections show blood vessel congestion and
severe synovitis with infiltration of lymphoid cells. (K) A pronounced osteolysis is also observed with the presence of granuloma, extensive neutrophil accumulation
and bone necrosis. (G) Sham CM condition reveals synovial membrane with intense infiltration of inflammatory cells and capillary vessels congestion and (L) extensive
number of osteoclasts. (H,M) UC-MSC-treated animals present milder granulomatous lesions than respective sham and hyperplasia of the synovial membrane ( ).
(I,J,N,O) CM-treated animals exhibit lower inflammation and bone destruction level. (I) CM2D image shows infiltration of lymphoid cells in a lower extent than
respective sham and (N) some degree of osteolysis. (J,O) CM3D image shows a synovial membrane with less blood vessels and cell infiltration than respective sham,
being the changes located in the extra-articular space. (P,Q) Control paw from a naïve animal shows normal histological features, with no evidence of inflammation
and with intact synovial membranes. (Panel II) Histological scores for synovial inflammation and bone erosion. Data represent the mean ± SEM. n = 3 for control; n =
4 for sham groups; n = 6 for all other groups. AC, articular cartilage; B, bone; G, granuloma; LC, lymphoid cells; O, osteolysis; OC, osteoclasts; SC, synovial cavity;
SM, synovial membrane.
Ultimately the results showed that CM3D has a clearly
superior capacity for both, avoiding and ameliorating AIA
manifestations in vivo when compared to CM2D or even UC-
MSCs. CM3D treatment was able to both prevent and revert all
major signs of AIA, including complete avoidance of necrotic
foci around the joints, acute and chronic inflammation, joint
deformity and secondary infection.
Mechanisms behind CM3D activity can also be extrapolated
based on secretome profile features resulting from our
comparative analysis. Mainly IL-10, a recognised potent
anti-inflammatory type II cytokine, plays a central role in
limiting host immune response to pathogens. Dysregulation
of IL-10 is associated with enhanced immunopathology in
response to infection as well as increased risk for development
of many autoimmune diseases (34, 44, 45). IL-10 was found
to be produced by innate cells, as well as CD4+ CD25−
Foxp3− and CD4+ CD25+ Foxp3+ Tregs using a Leishmania
chronic lesion model, which is consistent with our previous
observations that UC-MSCs enhanced CD4+ CD25+ Foxp3+
Tregs in response to a AIA environment in vivo (20, 46). IL-10
was also shown to limit the inflammasome (NLRP3)-driven
arthritic disease course and associated structural damage in an
AIA model (47). Furthermore, reversion of arthritis by IL-10
was not limited to AIA. IL-10 produced by B cells was also
found to be crucial for the suppression of Th17/Th1 responses,
induction of T regulatory type 1 cells and the reduction of
collagen-induced arthritis (CIA)-related signs, many common
to AIA (48). The recognised IL-10 distinctive capacities to
downregulate the production of pro-inflammatory cytokines
meant that it has been regarded as a potential therapeutic
agent for the treatment of arthritis (49). Besides IL-10, the
highly expressed leukaemia inhibitory factor (LIF) can augment
the immunosuppression capacity of CM3D through further
induction of Tregs (50–52). LIF may also play an important role
in regulating the neural-immune system interaction during early
acute inflammatory stages of the disease and the subsequent
healing and restitution process (53). Concomitantly, other
CM3D highly expressed factors such as FGF-2 and I-309,
have been found to be involved in different aspects of tissue
regeneration. FGF-2 through mitogenic and motogenic activities
over chondrocytes (39) and I-309 and SCF through promotion of
angiogenesis (27, 54). Yet other factors produced in CM3D, such
as SCF and G-CSF, have been found to support haematopoiesis
and recruiting of other CD 34− endogenous MSCs to aid in
regeneration (18, 28, 55). The remarkably low incidence of
secondary infection signs in animals treated with CM3D could
have been due to the relatively higher expression of cytokines
such GM-CSF, 6CKine, and eotaxin. Although these factors may
contribute to pathogenic inflammatory infiltrate, GM-CSF for
e.g., has even been used recently as primary immuno-target for
treatment of specific groups of RA patients (56), their synergistic
roles in stem cell stimulation and eosinophil recruitment
may confer advantages in a AIA context; especially when
coupled with the expression of anti-inflammatory cytokines
like IL-10 and LIF and within an environment characterised by
opportunistic secondary infection. Thus, in our experimental
conditions, GM-CSF, together with other cytokines usually
associated with RA pathogenesis, but with capacities to attract
lymphocytes with distinct phenotypes, like MIP-1α, MIP-1β,
6CKine, and RANTES, could be modulating specific T-cell
functions in favour of a wider host defence. In addition,
eotaxin could be attracting eosinophils to provide further
defence against infectious agents while producing antihistamines
(57–63).
Finally, differences seen between CM3D and CM2D could
also be explained by a distinctive pro-inflammatory character
of CM2D, as patented by a comparatively higher expression of
inflammatory MCP-1, IL-6, and IL-21 without counterbalancing
expression of anti-inflammatory cytokines. Both MCP-1 and
IL-6 have for long been found to be highly expressed in the
synovial fluid of RA patients (64). MCP-1 and IL-6 have been
consistently found to play critical roles in the development of
AIA signs in several animal models (31, 37, 65). Post-onset
treatment of AIA using endogenous MCP-1 inhibitors improved
clinical signs of arthritis and histological scores measuring
joint destruction, synovial lining, macrophage infiltration, and
bone erosion (66). In turn, IL-6 is synthesised in response to
many stimuli, including IL-1β which is widely implicated in the
pathogenesis of RA (36, 40). More recently, IL-21 has been found
to be involved in several mechanisms related to RA pathogenesis
being able to activate T cells, B cells, monocytes/macrophages
and synovial fibroblasts through activation of JAK-STAT,
MAPK, and PI3K/Akt signalling pathways, ultimately promoting
osteoclastogenesis (32).
Overall the results demonstrate the viability of applying this
3D-priming strategy to improve the efficacy of the resulting
UC-MSC secretome for counteracting the manifestations caused
by inflammatory arthritis. On the path to simplify MSC-
based therapeutic formulations more studies will now follow
to discriminate what components within CM3D are exerting
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the observed protective and therapeutic activities. This will
involve a concerted action applying multi-faceted analyses
involving exosome scrutiny, proteomics, metabolomics as well as
epigenomics and miRNA regulomics. A more difficult task will
be to define precise synergistic relationships between the different
actors within the formulations and predict their synergistic effect
within different disease environments. Nevertheless, we believe a
novel path has been unleashed, involving the use of well-defined
paracrine actors, instead of physical cells, as active substances for
“off-the-shelf ” Advanced Therapy Medicinal Products (ATMP).
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